Low-dose recombinant factor Vila for massive bleeding: A single centre observational cohort study with 73 patients

摘要

The aim of the study was to evaluate efficacy and safety of our in-house guideline recommending a low dose of 60 ug/kg for off-label use of recombinant factor Vila (rFVIIa) in massive bleeding.A single injection of 60 ug/kg rFVIIa appears to be efficacious in controlling massive bleeding, with a very low complication rate.rFVIIa is used off-label for massive bleeding without convincing evidence of the benefits but with recently documented increased risk for arterial thromboembolic events when used with a dose of >90 ug/kg. This paper reports the positive experience with our guideline for the treatment of massive bleeding with low dose rFVIIa.